Company / Current Liabilities
Dianthus Therapeutics, Inc. /DE/ Current Liabilities History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$30.7M
FY2025
5-year range
$8.2M / $30.7M
FY2021-FY2025
Trend
+66.6%
vs FY2024
Sector context
#175 of 213
Health Care
What the data says
Dianthus Therapeutics, Inc. /DE/'s current liabilities of $31M is lower than 82% of companies in the Health Care sector (FY2025). Current Liabilities has increased for 3 consecutive years, from $8M in FY2022 to $31M in FY2025.
Based on SEC 10-K filings.
$31M in FY2025 with a 5-year CAGR of +21.9%.
Increased from $10M to $31M over the past 2 years.
Health Care sector context is included.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- +55.2%
- 5-Year CAGR
- +21.9%
- 10-Year CAGR
- -
Sector benchmark
Top 18% in Health CareTop 18% of 213This company $30.7M Sector average $1.6B
▼
-98.1% below sector average
Key checks
Key Insights
- Dianthus Therapeutics, Inc. /DE/'s current liabilities has grown for 3 consecutive years.
- 5-year CAGR of +21.9%, indicating consistent growth.
- In FY2025, current liabilities increased 66.6% year-over-year.
- Ranks #175 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 4.46 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $30.7M | +66.6% |
| FY2024 | $18.5M | +91.6% |
| FY2023 | $9.6M | +17.1% |
| FY2022 | $8.2M | -24.3% |
| FY2021 | $10.9M | -5.0% |
| FY2020 | $11.4M | -19.0% |
| FY2019 | $14.1M | +35.5% |
| FY2018 | $10.4M | +151.5% |
| FY2017 | $4.1M | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026